Published on 3 Aug 2022 on Zacks via Yahoo Finance
Moderna (MRNA) Beats on Q2 Earnings, Starts $3B Buyback Program
Moderna, Inc. MRNA reported earnings of $5.24 per share for the second quarter of 2022, beating the Zacks Consensus Estimate of $4.45. The company had reported earnings of $6.46 per share in the year-ago quarter. The year-over-year decline in the bottom line was due to higher operating expenses incurred during the second quarter.
Revenues in the quarter were $4.75 billion, significantly beating the Zacks Consensus Estimate of $3.85 billion. Total revenues were up 9.1% year over year, driven by increasing product sales, entirely from the COVID-19 vaccine.
Quarter in Detail